中国药理学通报
中國藥理學通報
중국약이학통보
CHINESE PHARMACOLOGICAL BULLETIN
2014年
6期
857-861,862
,共6页
汪和贵%王森%陈艳红%邹建刚%柯永胜
汪和貴%王森%陳豔紅%鄒建剛%柯永勝
왕화귀%왕삼%진염홍%추건강%가영성
心力衰竭%钾通道%β1-肾上腺素受体%蛋白激酶A%钙调蛋白激酶Ⅱ%膜片钳技术
心力衰竭%鉀通道%β1-腎上腺素受體%蛋白激酶A%鈣調蛋白激酶Ⅱ%膜片鉗技術
심력쇠갈%갑통도%β1-신상선소수체%단백격매A%개조단백격매Ⅱ%막편겸기술
heart failure%potassium channel%β1-ad-renergic receptor%protein kinase A%calmodulin kina-ses II%patch-clamp technique
目的:探讨β1-肾上腺受体(β1-AR)激活对慢性心衰( CHF)豚鼠心室肌细胞快激活延迟整流钾电流( IKr )的影响及机制。方法制备豚鼠CHF模型,采用全细胞膜片钳技术记录心室肌细胞IKr ,观察选择性β1-AR激动剂对CHF心室肌细胞IKr的影响,并采用蛋白激酶A( PKA)及钙调蛋白激酶Ⅱ( CaMKⅡ)抑制剂干预研究其机制。结果β1-AR激动剂扎莫特罗使CHF心室肌细胞IKr减少了(52±8)%,延长动作电位时程。β1-AR阻滞剂CGP20712A完全抑制扎莫特罗对CHF心室肌细胞IKr的减弱作用。应用PKA抑制剂KT5720预处理,扎莫特罗仅使CHF心室肌细胞IKr减少了(28±3)%。应用CaMKⅡ抑制剂KN93预处理,KN93不能减弱扎莫特罗对CHF心室肌细胞IKr的抑制作用。结论β1-AR激活抑制 CHF 心室肌细胞 IKr;心衰时β1-AR 通过PKA通路抑制心室肌细胞IKr ,与CaMKⅡ通路无关。
目的:探討β1-腎上腺受體(β1-AR)激活對慢性心衰( CHF)豚鼠心室肌細胞快激活延遲整流鉀電流( IKr )的影響及機製。方法製備豚鼠CHF模型,採用全細胞膜片鉗技術記錄心室肌細胞IKr ,觀察選擇性β1-AR激動劑對CHF心室肌細胞IKr的影響,併採用蛋白激酶A( PKA)及鈣調蛋白激酶Ⅱ( CaMKⅡ)抑製劑榦預研究其機製。結果β1-AR激動劑扎莫特囉使CHF心室肌細胞IKr減少瞭(52±8)%,延長動作電位時程。β1-AR阻滯劑CGP20712A完全抑製扎莫特囉對CHF心室肌細胞IKr的減弱作用。應用PKA抑製劑KT5720預處理,扎莫特囉僅使CHF心室肌細胞IKr減少瞭(28±3)%。應用CaMKⅡ抑製劑KN93預處理,KN93不能減弱扎莫特囉對CHF心室肌細胞IKr的抑製作用。結論β1-AR激活抑製 CHF 心室肌細胞 IKr;心衰時β1-AR 通過PKA通路抑製心室肌細胞IKr ,與CaMKⅡ通路無關。
목적:탐토β1-신상선수체(β1-AR)격활대만성심쇠( CHF)돈서심실기세포쾌격활연지정류갑전류( IKr )적영향급궤제。방법제비돈서CHF모형,채용전세포막편겸기술기록심실기세포IKr ,관찰선택성β1-AR격동제대CHF심실기세포IKr적영향,병채용단백격매A( PKA)급개조단백격매Ⅱ( CaMKⅡ)억제제간예연구기궤제。결과β1-AR격동제찰막특라사CHF심실기세포IKr감소료(52±8)%,연장동작전위시정。β1-AR조체제CGP20712A완전억제찰막특라대CHF심실기세포IKr적감약작용。응용PKA억제제KT5720예처리,찰막특라부사CHF심실기세포IKr감소료(28±3)%。응용CaMKⅡ억제제KN93예처리,KN93불능감약찰막특라대CHF심실기세포IKr적억제작용。결론β1-AR격활억제 CHF 심실기세포 IKr;심쇠시β1-AR 통과PKA통로억제심실기세포IKr ,여CaMKⅡ통로무관。
Aim To investigate the effects of β1-ad-renergic receptor (β1-AR ) on rapid component of the delayed rectifier potassium current ( IKr ) in ventricular <br> myocytes of guinea pigs with chronic heart failure ( CHF) . Methods The CHF model of guinea pigs was established by descending thoracic aortic banding . <br> Whole-cell patch-clamp technique was used to record IKr in ventricular myocytes. The effects ofβ1-AR on IKr in CHF ventricular myocytes were detected and its mechanisms were studied by pretreatment with protein kinase A ( PKA ) inhibitor and calmodulin kinase II( CaMK II) inhibitor. Results In CHF ventricular myocytes, xamoterol, the selectiveβ1-AR agonist, de-creased IKr by (52±8)% and prolonged action poten-tial duration. These effects were completely abolished by pretreatment of myocytes with CGP20712A, a selec-tive β1-AR antagonist. íamoterol only decreased IKr <br> by (28±3)% by pretreatment of CHF myocytes with specific PKA inhibitor KT5720 . KN93 , an inhibitor of CaMKII, did not attenuate the inhibitory effect on CHF ventricular myocytes. Conclusion IKr is inhibi-ted by β1-AR activation in CHF ventricular myocytes. PKA, but not CaMKII signaling pathway is involved in, at least in part, the inhibitory effect ofβ1-AR acti-vation on IKr.